 joins FDA’s Office of New  Drug Quality Assessment (Rockville, MD, 

) as the associate director  for biopharmaceutics. Since joining FDA in 1997, Selen has been in the office  of clinical pharmacology and has been actively involved in several FDA  initiatives related to pediatrics.  

 has been  appointed as the director for the Office of Drug Evaluation III (Rockville, MD, 

). Beitz has had a 12-year  career at FDA involving both pre- and post-approval regulatory activities.  Since January 2006, she has served as the acting director of the Office of Drug  Evaluation III.

News

Dr. Arzu Selen joins FDA's Office of New Drug Quality Assessment (Rockville, MD, www.fda.gov/cder) as the associate director for biopharmaceutics.